

DAFTAR PUSTAKA

- Abu-Freha, N., Abu-Kosh, O., Yardeni, D., Ashur, Y., Abu-Arar, M., Yousef, B., 2023. *Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents*. <https://doi.org/10.3390/life13091872>
- Azzeri, A., Shabaruddin, F. H., Tan, S.-S., Dahlui, M., McDonald, S. A., Kamarulzaman, A. 2018. Clinical characteristics of patients with chronic hepatitis c infection at initial presentation to tertiary care in an Asian middle-income country. *Southeast Asian Journal of Tropical Medicine and Public Health*, 49(5)
- Bayupurnama, P., 2012. Tatalaksana Hepatitis B dan C kronik dalam praktek klinik sehari – hari. Nuha Medika, Yogyakarta.
- Besheer, T., Razek, A. A. K. A., El Bendary, M., Abd El Maksoud, M., 2017. Does steatosis affect the performance of diffusion-weighted MRI values for fibrosis evaluation in patients with chronic hepatitis C genotype 4?. *The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology*, 28(4), 283–288.
- Balmaceda, J. B., Aepfelbacher, J., Belliveau, O., Chaudhury, C. S., Chairez, C., 2019. Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV. *Antiviral therapy*, 24(4), 451–457. <https://doi.org/10.3851/IMP3327>
- Castéra, L., Vergniol, J., Foucher, J., Le Bail, B., Chanteloup, 2005. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology*, 128(2), 343–350. <https://doi.org/10.1053/j.gastro.2004.11.018>
- Castéra, L., Vergniol, J., Foucher, J., Le Bail, B., Chanteloup, E., Haaser., 2005. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology*, 128(2), 343-350.
- Caligiuri, A., Gentilini, A., Pastore, M., Gitto, S., & Marra, F. 2021. Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression. *Cells*, 10(10), 2759. <https://doi.org/10.3390/cells10102759>
- Carmona, I., Cordero, P., Ampuero, J., Rojas, A., & Romero-Gómez, M. (2016). Role of assessing liver fibrosis in management of chronic hepatitis C virus infection. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*, 22(10), 839–845. <https://doi.org/10.1016/j.cmi.2016.09.017>

- Cheng, C. H., Chu, C. Y., Chen, H. L., Lin, I. T., Wu, C. H., 2021. Direct-acting antiviral therapy of chronic hepatitis C improves liver fibrosis, assessed by histological examination and laboratory markers. *Journal of the Formosan Medical Association*, 120(5), 1259-1268.
- Curry, M. P., O'Leary, J. G., Bzowej, N., Muir, A. J., Korenblat, K. 2015. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. *The New England journal of medicine*, 373(27), 2618–2628. <https://doi.org/10.1056/NEJMoa1512614>
- Chopra, S. 2023. Clinical manifestations and natural history of chronic hepatitis C virus infection. In TW: Bisceglie, A.M (Ed) *UpToDate*, Accesible On Feb 2024
- Collazos, J., Pérez-Is, Y, Fuente, B., Morano L., Rivas-Carmenado, M., Rodriguez, M. 2024. No gender differences in the 24-month course of non-invasive liver fibrosis markers after DAA therapy in HCV-mono and HCV/HIV-coinfected patients. *Dental science reports*, 14 Available from: 10.1038/s41598-024-57845-x
- Chuaypen, N., Siripongsakun, S., Hiranrat, P., Tanpowpong, N., Avihingsanon, A. 2022. Improvement of liver fibrosis, but not steatosis, after HCV eradication as assessment by MR-based imaging: Role of metabolic derangement and host genetic variants. *PloS one*, 17(6), <https://doi.org/10.1371/journal.pone>
- Dahlan S. (2016). *Besar sampel dalam penelitian kedokteran dan kesehatan*. Jakarta: Epidemiologi Indonesia.
- Dahlan S. (2019). *Analisis Multivariate Regresi Logistik*. Jakarta: Epidemiologi Indonesia.
- Di Mauro, S., Scamporrino, A., Filippello, A., Di Pino, A., Scicali, R., Malaguarnera, R., et al., 2021. Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. *Int. J. Mol. Sci.* 22, 11905.
- de Franchis, R., Bosch, J., Garcia-Tsao, G., Reiberger, T., Ripoll, C., & Baveno VII Faculty (2022). Baveno VII - Renewing consensus in portal hypertension. *Journal of hepatology*, 76(4), 959–974. <https://doi.org/10.1016/j.jhep.2021.12.022>
- de Torres, M., & Poynard, T. (2003). Risk factors for liver fibrosis progression in patients with chronic hepatitis C. *Annals of hepatology*, 2(1), 5–11
- Dixon, J.B., Bhathal, P.S., O'Brien, P.E., 2001. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. *Gastroenterology* 121, 91–100

- Elsharkawy, A., Samir, R., El-Kassas, M., 2022. Fibrosis regression following hepatitis C antiviral therapy. *World journal of hepatology*, 14(6), 1120–1130. <https://doi.org/10.4254/wjh.v14.i6.1120>
- Ferreira, J., Bicho, M., & Serejo, F. 2024. Effects of HCV Clearance with Direct Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic Parameters. *Viruses*, 16(3) <https://doi.org/10.3390/v16030371>
- Friedman, S.L., 2023. Pathogenesis of hepatic fibrosis. In TW Runyon, B.A. (Ed). *UpToDate*, available on Jan 2024
- Graham, P. 2022. Hepatitis C: epidemiology, transmission and presentation, wchh.onlinelibrary.wiley.com <https://doi.org/10.1002/psb.1992>
- Grgurevic, I., Bozin, T., & Madir, A. (2017). Hepatitis C is now curable, but what happens with cirrhosis and portal hypertension afterwards?. *Clinical and experimental hepatology*, 3(4), 181–186. <https://doi.org/10.5114/ceh.2017.71491>
- Hassan, W. A., Kamel, S. I., Mahmoud, I. A. N., Makhoulouf, N., Moubark, M., 2023. Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs). *Egyptian Liver Journal*, 13(1), 49.
- Im, G. Y., & Dieterich, D. T. (2012). Direct-acting antiviral agents in patients with hepatitis C cirrhosis. *Gastroenterology & hepatology*, 8(11), 727–765
- Khan, S., & Saxena, R. 2021. Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review. *Advances in anatomic pathology*, 28(6), 408–414. <https://doi.org/10.1097/PAP.0000000000000312>
- Leuştean, A., Popescu, C., Nichita, L., Tilişcan, C., & Aramă, V. 2021. Dynamics of APRI and FIB-4 in HCV cirrhotic patients who achieved SVR after DAA therapy. *Experimental and therapeutic medicine*, 21(1), 99. <https://doi.org/10.3892/etm.2020.9531>
- Laursen, T. L., Siggaard, C. B., Kazankov, K., Sandahl, T. D., Møller, H. J., Tarp, B., 2020. Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C. *Journal of viral hepatitis*, 27(1), 28–35. <https://doi.org/10.1111/jvh.13204>
- Li M, Zong Z, Xiong X, Fan J, Zhong H, Liu N, Ye W and Jing J (2023) Ascites re compensation in HBV-related first decompensated cirrhosis after anti-viral therapy. *Front. Cell. Infect. Microbiol.* 12:1053608. doi: 10.3389/fcimb.2022.1053608

- Lourenço, M. S., Zitelli, P. M. Y., Cunha-Silva, M., Oliveira, A. I. N., Oliveira, C. P., Sevá-Pereira, T., Carrilho, F. J., Pessoa, M. G., & Mazo, D. F. (2022). Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil. *World journal of hepatology*, 14(1), 195–208. <https://doi.org/10.4254/wjh.v14.i1.195>
- Leslie, Phillip, Miranda. 2022. From fatty liver to nonalcoholic steatohepatitis with fibrosis. 147-173. doi: 10.1016/b978-0-323-99764-5.00013-5
- Landis, J. R., & Koch, G. G. (1977). The measurement of observer agreement for categorical data. *Biometrics*, 33(1), 159–174. doi:10.2307/2529310
- Mauro, E., Crespo, G., Montironi, C., Londoño, M. C., Hernández-Gea, V., Ruiz, P. 2018. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. *Hepatology* (Baltimore, Md.), 67(5), 1683–1694. <https://doi.org/10.1002/hep.29557>
- Melianti, I., Ratnasari, N., Indrarti, F., 2022. Peran direct acting antiviral terhadap perbaikan fibrosis pada pasien hepatitis c kronik di RSUP Dr Sardjito (Tesis)
- Muljono D,H. (2017). Epidemiology of Hepatitis B and C in Republic of Indonesia. *Euroasian journal of hepato-gastroenterology*, 7(1), 55–59. <https://doi.org/10.5005/jp-journals-10018-1212>
- McCormick, P & Jalan, R., (2018). *Sherlock's Diseases of the Liver and Biliary System*, Thirteenth Edition. Edited by James S. Dooley, Anna S. F. Lok, Guadalupe Garcia-Tsao and Massimo Pinzani. John Wiley & Sons Ltd. 107
- Nakajima, T., Karino, Y., Hige, S., Suii, H., Tatsumi, R., Yamaguchi, M., 2022.
- Aging impairs fibrosis-4 index after sustained virologic response by direct-acting antivirals in chronic hepatitis C infection. *Annals of Hepatology*, 27(1), 100566.
- Nadzhan, M, Ratnasari, N., Triwikatmani, C., 2020, Prevalence of Chronic Hepatitis C during 2015-2018 at Dr Sardjito General hospital (Paper)
- Naim, Abu-Freha., Osama, Abu-Kosh., David, Yardeni., 2023. Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents. doi: 10.3390/life13091872
- Nitescu, M., Vâjăitu, C., Săndulescu, O., Săndulescu, O., Streinu-Cercel, A., Streinu-Cercel, 2017. Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals. *Revista Romana De Medicina De Laborator*. <https://doi.org/10.1515/RRLM-2017-0030>

- Ogasawara, N., Kobayashi, M., Akuta, N., Kominami, Y., Fujiyama, S., Kawamura., 2018. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b. *Journal of medical virology*, 90(2), 313–319. <https://doi.org/10.1002/jmv.24950>
- Pockros, P.J. 2023. Direct-acting antivirals for the treatment of hepatitis C virus infection. In TW Bisceglie, A.M (Ed) *UpToDate*, Accesible On Jan 2024
- Quaranta, M. G., Ferrigno, L., Tata, X., D'Angelo, F., Coppola, C., Ciancio, A., ... & Kondili, L. A. 2021. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort. *BMC Infectious Diseases*, 21, 1-9.
- Rockey, D. C., & Friedman, S. L. (2021). Fibrosis regression after eradication of hepatitis C virus: from bench to bedside. *Gastroenterology*, 160(5), 1502-1520.
- Ramachandran, P., & Iredale, J. P. (2012). Liver fibrosis: a bidirectional model of fibrogenesis and resolution. *QJM: An International Journal of Medicine*. <https://doi.org/10.1093/QJMED/HCS069>
- Rosato, V., Ascione, A., Nevola, R., Fracanzani, A. L., Piai, G., Messina, V., 2022 Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study. *Journal of viral hepatitis*, 29(1), 26–34. <https://doi.org/10.1111/jvh.13617>
- Rockey, D. C., & Friedman, S. L. 2021. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside. *Gastroenterology*, 160(5), 1502–1520.e1. <https://doi.org/10.1053/j.gastro.2020.09.065>
- Rungta, S., Kumari, S., Deep, A., Verma, K., Swaroop, S., 2021. APRI and FIB-4 performance to assess liver fibrosis against predefined Fibroscan values in chronic hepatitis C virus infection. *J Family Med Prim Care* 10:4082-8.
- Sari D,A, Sutarga I., 2021. *Arc. Com. Health • Agustus 2021* p-ISSN 2302-139X e-ISSN 2527-3620. Vol. 8 No. 2: 204 – 215
- Soliman, H., Ziada, D., Salama, M., Hamisa, M., Badawi, R., Hawash, N., 2020. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study. *Endocrine, metabolic & immune disorders drug targets*, 20(1), 104–111. <https://doi.org/10.2174/1871530319666190826150344>
- Sirinawasatien, A., & Supawan, P. 2024. Sustained virological response in chronic hepatitis C patients by direct-acting antiviral treatment significantly reduces liver stiffness over 24 weeks posttreatment. *Medicine*, 103(19), e38096. <https://doi.org/10.1097/MD.00000000000038096>

- Sulaiman Dr, A. S., Hasan Dr, I., Lesmana Dr, C. R. A., Kurniawan Dr, J., Aprilicia, G., Nugroho Dr, Y., ... & Sulaiman, B. S. Kombinasi Sofosbuvir-Ledipasvir dan Sofosbuvir-Daclatasvir pada Pengobatan Pasien Hepatitis C di Indonesia. *Jurnal Penyakit Dalam Indonesia*, 10(4), 3.
- Singh, S., Facciorusso, A., Loomba, R., & Falck-Ytter, Y. T. (2018). Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*, 16(1), 27–38.e4. <https://doi.org/10.1016/j.cgh.2017.04.038>
- Saadany, S.E, Soliman, H, Ziada, D.H, Hamisa,M., Hefeda,M., Selim, A. 2016.Fibroscan versus liver biopsy in the evaluation of response among the Egyptian HCV infected patients to treatment, *The Egyptian Journal of Radiology and Nuclear Medicine*, Volume 47, Issue 1, 2016
- Tag-Adeen, M., Sabra, A.M., Akazawa, Y., Ohnita, K., 2017. Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement. *Hepatic Medicine: Evidence and Research* 9:45-53.
- Wilder, J., Patel, K., 2014. The clinical utility of FibroScan((R) as a noninvasive diagnostic test for liver disease. *Med. Devices*. 7, 107–114.
- Wang, Y., Ma, X., Zou, Y., Yue, M., Zhang, M., Yu, R., Chen., 2024. Evaluating short-term and long-term liver fibrosis improvement in hepatitis C patients post-DAA treatment. *Journal of biomedical research*, 1–10. Advance online publication. <https://doi.org/10.7555/JBR.37.20230284>
- Wang, Q., Zhao, H., Deng, Y., Zheng, H., Xiang, H., Nan, Y., ... & Jia, J. (2022). Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis. *Journal of Hepatology*, 77(6), 1564-1572.
- Yoo, H.W., Park, J.Y., Kim, S.G., Jung, Y.K., Lee, S.H., Kim, M. 2022. Regression of liver fbrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents. *Scientific Reports* 12:193